Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$21.21 USD

21.21
440,154

+0.26 (1.24%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $21.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $52.35, marking a -0.85% move from the previous day.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.

Zacks Equity Research

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree

by Zacks Equity Research

Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree are part of the Zacks top Analyst Blog.

Tirthankar Chakraborty headshot

5 Top Growth Stocks to Buy as Recession Fears Subside

by Tirthankar Chakraborty

Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.

Zacks Equity Research

Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's

by Zacks Equity Research

Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $55.45, representing a -0.84% change from its previous close.

Zacks Equity Research

Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members

by Zacks Equity Research

Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $56.14, representing a +1.15% change from its previous close.

Zacks Equity Research

Centene (CNC) Sells Circle Health to Boost Managed Care Business

by Zacks Equity Research

Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.

Vaishali Doshi headshot

Snap these 4 Top-Ranked Liquid Stocks to Drive Solid Returns

by Vaishali Doshi

Here are four top-performing liquid stocks, American Public Education (APEI), Amphastar Pharmaceuticals (AMPH), GigaCloud (GCT) and Oceaneering International (OII), which investors can add to their portfolio to boost returns.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $54.03, signifying a -1.44% move from its prior day's close.

Zacks Equity Research

Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $62.74, signifying a -1.12% move from its prior day's close.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Is Up 1.53% in One Week: What You Should Know

by Zacks Equity Research

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Here's Why You Should Retain Centene (CNC) Stock For Now

by Zacks Equity Research

Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.

Vaishali Doshi headshot

4 Promising Liquid Stocks to Boost Your Portfolio in 2024

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), Vimeo (VMEO) and Fluor Corporation (FLR), which investors can add to their portfolio for solid gains

Zacks Equity Research

Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?

by Zacks Equity Research

Here is how Arch Therapeutics, Inc. (ARTH) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Think Amphastar (AMPH) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

by Zacks Equity Research

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Zacks Equity Research

Zacks.com featured highlights include Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings

by Zacks Equity Research

Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings are part of the Zacks Screen of the Week article.

Zacks Equity Research

Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run?

by Zacks Equity Research

Diversified treatment network, solid patient volumes in the Hospital segment and robust cash flows continue to drive Tenet Healthcare (THC).

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Nilanjan Choudhury headshot

5 Good Opportunities on Relative Price Strength Strategy

by Nilanjan Choudhury

AMPH, FOUR, BECN, HOFT and HTH are five stocks with explosive relative price strength.

Zacks Equity Research

3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock

by Zacks Equity Research

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.